Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Clinical Lymphoma|March 30, 2005
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemiaZachary R Hunter, Andrew R Branagan, Robert Manning, et al.
Seminars in Oncology|April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaMorie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.
Blood Advances|March 14, 2025
Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injuryE Bridget Kim, Jack E Malespini, Matthew Lei, et al.
Seminars in Oncology|April 30, 2003
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRobert A Kyle, Steven P Treon, Raymond Alexanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemiaSteven P Treon, Mark Hansen, Andrew R Branagan, et al.
Blood Cancer Journal|November 1, 2022
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myelomaKevin Charles Miller, Patrick Connor Johnson, Jeremy S Abramson, et al.
Seminars in Oncology|April 30, 2003
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRoger G Owen, Steven P Treon, Ayad Al-Katib, et al.
Blood|November 19, 2008
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaSteven P Treon, Andrew R Branagan, Leukothea Ioakimidis, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2017
Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm TrialAndrew R Branagan, Eamon Duffy, Randy A Albrecht, et al.
Clinical Lymphoma & Myeloma|February 28, 2007
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapyEvdoxia Hatjiharissi, Mark Hansen, Daniel Ditzel Santos, et al.
Pageof 6